Ebola strain bypasses 3.5m vaccines

More than 1,000 suspected infections. Over 240 deaths. Health workers trying to operate inside an active war zone. And no approved vaccine for the virus driving the outbreak.

The crisis in eastern Congo has exposed a weakness in a decade of Ebola planning: the vaccines and treatments the world has built up are aimed at a different Ebola virus from the one now spreading.

A Key Cut for the Wrong Lock

The virus circulating in the Democratic Republic of Congo's Ituri Province is the Bundibugyo species of Ebola, first identified in Uganda in 2007. It has surfaced only twice before, in outbreaks small enough to draw little international attention. That rarity is now the problem. Every Ebola vaccine developed since the 2014 West Africa epidemic targets the Zaire species.

Vaccines train the immune system to recognise a particular protein on the surface of a virus, known as a glycoprotein. Merck's Ervebo, the vaccine that helped bring recent Zaire outbreaks under control, teaches the body to recognise Zaire's version. Bundibugyo's glycoprotein differs by roughly 30% in its genetic sequence, enough to make protection uncertain.

The WHO brought experts together in late May and concluded that evidence on cross-protection is "very limited and insufficient". A small primate study found partial survival after use of the Zaire vaccine, but every vaccinated animal still became ill. The approved antibody treatments, Inmazeb and Ebanga, are similarly not expected to work. The global stockpile contains more than 3.5 million doses of Ervebo, all designed for a pathogen that is not the one in circulation.

Outrunning the Response

WHO declared the outbreak a Public Health Emergency of International Concern on May 17, two days after the DRC officially announced it. That speed tells its own story. By the time laboratories confirmed Bundibugyo, the virus had already moved well beyond the neat boundaries of a conventional response. As of early June, roughly 282 cases had been confirmed in laboratories, with 42 deaths, while suspected cases had passed 1,000.

The conflict in eastern Congo makes every public health measure harder. The M23 rebel group controls cities in neighbouring provinces, including Goma, a city of more than one million people on the Rwandan border. ADF fighters killed seven people in Beni, another area hit by the outbreak. Hundreds of diagnostic samples remain untested. Uganda has confirmed nine cases and closed its border.

Two vaccine candidates are being pushed forward. Oxford's ChAdOx1 platform, adapted from the AstraZeneca Covid vaccine technology, could produce trial doses in two to three months. A second candidate from IAVI, using a harmless livestock virus as a carrier to deliver Bundibugyo proteins, needs seven to nine months. Neither has been tested in humans. Gavi has committed $50 million to accelerate production once there is efficacy data.

What Europe Learned It Can't Do

One confirmed Ebola case has reached EU soil: a US healthcare worker admitted to Berlin's Charité hospital on May 20. An Italian MSF surgeon evacuated to Rome's Spallanzani Institute tested negative. Two suspected cases in Brazil turned out to be meningitis and malaria. The ECDC assesses the risk to European citizens as very low.

The outbreak is unlikely to spread across Europe. Still, it has shown the limit of the EU's post-Covid health architecture. HERA, the agency created to secure vaccines and medical countermeasures in emergencies, has built joint procurement mechanisms and 22 strategic stockpiles across member states. That worked for monkeypox in 2022, when an approved vaccine already existed. For Bundibugyo, there is nothing ready to buy. The EU has instead allocated €7.4 million to WHO for clinical trials, paying into a response it cannot supply itself.

National systems are moving on separate tracks. Italy has issued a five-level risk classification with mandatory health declarations for arrivals from the DRC and Uganda. Germany relies on seven specialised isolation stations. France has reinforced surveillance at Mayotte but has no unified quarantine protocol aligned with other member states.

The world spent billions preparing for the last Ebola. Bundibugyo was, as German health experts put it, a "commercially uninteresting" strain, rare enough to be ignored until it was not rare anymore. Whether this outbreak drives serious investment in broad-spectrum Ebola vaccines, or simply fades when the emergency does, will say more about pandemic preparedness than any framework written after Covid.